Acasti Pharma Inc. (ACST) Q3 2020 Results Conference Call February 14, 2020 1:00 PM ET
Company Participants
David Waldman - IR
Jan D’Alvise - President and CEO
Pierre Lemieux - COO, Chief Scientific Officer and Co-Founder
Brian Groch - Chief Commercial Officer
Jean-François Boily - VP, Finance
Conference Call Participants
Leland Gershell - Oppenheimer
Toby Ma - Mackie Research
Operator
Ladies and gentlemen, Hello and thank you all for your patience and for joining today’s Acasti Pharma Third Quarter 2020 Business Update Conference Call. All participants are in a listen-only mode, but you will have an opportunity to ask questions after today’s prepared remarks. Today’s session is being recorded.
And with that, I am pleased to turn the floor over to Mr. David Waldman with Investor Relations. Welcome, David.
David Waldman
Thank you. Good afternoon, everyone and welcome to Acasti Pharma’s third quarter fiscal 2020 conference call. On the call with us this afternoon are Jan D’Alvise, President and CEO; Pierre Lemieux, Chief Operating Officer, Chief Scientific Officer and Co-Founder; Brian Groch, Chief Commercial Officer; and Jean-François Boily, Vice President, Finance.
If you have any questions after the call or would like any additional information about the Company, please contact Crescendo Communications at 212-671-1020.
I’d also like to remind everyone that statements on this conference call that are not statements of historical or current facts, constitute forward-looking information within the meaning of the Canadian Securities Laws and forward-looking statements within the meaning of U.S. Federal Security Laws. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
In addition to statements which explicitly describe such risks and uncertainties, readers are urged
- Read more current GRCE analysis and news
- View all earnings call transcripts